PACAB-002 is designed to prevent recurrence in ovarian cancer
PACAB-002 is engineered to target peritoneal micrometastases that are difficult to eradicate with current standard-of-care treatment. This is an important challenge in high-grade serous ovarian cancer (HGSOC), as intraperitoneal recurrence is a key driver of poor survival.
The European Medicines Agency (EMA) has granted orphan drug designation to PACAB-002. In granting the designation, the EMA recognises the strong preclinical efficacy data of PACAB-002 and its potential to provide a clinically relevant benefit over existing treatment options in ovarian cancer.
Ovarian cancer has high recurrence caused by peritoneal micrometastases
Systemic treatment is not sufficient to eradicate micrometastases located in the peritoneal cavity, a key driver of recurrence and poor survival. Intraperitoneal administration of chemotherapy has shown effect, but rapid drainage significantly limits effective dose and increases systemic toxicity.
PACAB-002 combines local delivery, tumor-accumulation, and tissue-adhesion to enable drug retention and prolonged efficacy while reducing toxicity.
PACAB-002 combines NaDeNo’s technology and an approved API with known efficacy
Polymer matrix encapsulating the API without any chemical modification, while protecting it from degradation until it is released
Encapsulated active pharmaceutical ingredient (API) of PACAB-002, cabazitaxel, a second-generation taxane with known efficacy
Surface chemistry that accumulates at tumor tissue at a 10-to-1 ratio, while being “sticky” for retention and prolonged efficacy
This example preclinical trial of an ovarian cancer mouse model shows that median survival doubled with single IP dose as compared to free drug, and survival increased to 100% with two IP doses.
PACAB-002 shows peritoneal retention, tumor accumulation and survival benefit in preclinical studies
2X PACAB-002
1X PACAB-002
All animals alive at day 100
Free drug
40 days
81 days
Untreated
25 days